ID   TADBP_HUMAN             Reviewed;         414 AA.
AC   Q13148; A4GUK4; A4GUK5; A4GUK6; B2R629; B4DJ45; E2PU12; Q53H27; Q6FI92;
AC   Q96DJ0;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   18-JUN-2025, entry version 241.
DE   RecName: Full=TAR DNA-binding protein 43 {ECO:0000303|PubMed:7745706};
DE            Short=TDP-43 {ECO:0000303|PubMed:7745706};
GN   Name=TARDBP {ECO:0000303|PubMed:18396105,
GN   ECO:0000312|HGNC:HGNC:11571};
GN   Synonyms=TDP43 {ECO:0000303|PubMed:7745706};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=7745706; DOI=10.1128/jvi.69.6.3584-3596.1995;
RA   Ou S.-H.I., Wu F., Harrich D., Garcia-Martinez L.F., Gaynor R.B.;
RT   "Cloning and characterization of a novel cellular protein, TDP-43, that
RT   binds to human immunodeficiency virus type 1 TAR DNA sequence motifs.";
RL   J. Virol. 69:3584-3596(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, AND
RP   UBIQUITINATION.
RX   PubMed=17481916; DOI=10.1016/j.mcn.2007.03.007;
RA   Strong M.J., Volkening K., Hammond R., Yang W., Strong W.,
RA   Leystra-Lantz C., Shoesmith C.;
RT   "TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding
RT   protein.";
RL   Mol. Cell. Neurosci. 35:320-327(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, and Substantia nigra;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 122-136 AND 276-293, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Afjehi-Sadat L.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [11]
RP   PROTEIN SEQUENCE OF 252-263; 276-293 AND 409-414, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION, AND UBIQUITINATION.
RX   PubMed=17023659; DOI=10.1126/science.1134108;
RA   Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C.,
RA   Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F.,
RA   Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W.,
RA   Kretzschmar H.A., Trojanowski J.Q., Lee V.M.-Y.;
RT   "Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic
RT   lateral sclerosis.";
RL   Science 314:130-133(2006).
RN   [12]
RP   FUNCTION.
RX   PubMed=11285240; DOI=10.1093/emboj/20.7.1774;
RA   Buratti E., Doerk T., Zuccato E., Pagani F., Romano M., Baralle F.E.;
RT   "Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR
RT   exon 9 skipping.";
RL   EMBO J. 20:1774-1784(2001).
RN   [13]
RP   RNA-BINDING, AND MUTAGENESIS.
RX   PubMed=11470789; DOI=10.1074/jbc.m104236200;
RA   Buratti E., Baralle F.E.;
RT   "Characterization and functional implications of the RNA binding properties
RT   of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9.";
RL   J. Biol. Chem. 276:36337-36343(2001).
RN   [14]
RP   SUBCELLULAR LOCATION, AND MOTIF.
RX   PubMed=18957508; DOI=10.1242/jcs.038950;
RA   Ayala Y.M., Zago P., D'Ambrogio A., Xu Y.F., Petrucelli L., Buratti E.,
RA   Baralle F.E.;
RT   "Structural determinants of the cellular localization and shuttling of TDP-
RT   43.";
RL   J. Cell Sci. 121:3778-3785(2008).
RN   [15]
RP   INTERACTION WITH HNRNPA2B1.
RX   PubMed=19429692; DOI=10.1093/nar/gkp342;
RA   D'Ambrogio A., Buratti E., Stuani C., Guarnaccia C., Romano M., Ayala Y.M.,
RA   Baralle F.E.;
RT   "Functional mapping of the interaction between TDP-43 and hnRNP A2 in
RT   vivo.";
RL   Nucleic Acids Res. 37:4116-4126(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=19765185; DOI=10.1111/j.1471-4159.2009.06383.x;
RA   Colombrita C., Zennaro E., Fallini C., Weber M., Sommacal A., Buratti E.,
RA   Silani V., Ratti A.;
RT   "TDP-43 is recruited to stress granules in conditions of oxidative
RT   insult.";
RL   J. Neurochem. 111:1051-1061(2009).
RN   [18]
RP   SUBUNIT.
RX   PubMed=20043239; DOI=10.1007/s10571-009-9489-9;
RA   Shiina Y., Arima K., Tabunoki H., Satoh J.;
RT   "TDP-43 dimerizes in human cells in culture.";
RL   Cell. Mol. Neurobiol. 30:641-652(2010).
RN   [19]
RP   INTERACTION WITH ATXN2, AND CHARACTERIZATION OF VARIANT ALS10 LYS-331.
RX   PubMed=20740007; DOI=10.1038/nature09320;
RA   Elden A.C., Kim H.J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X.,
RA   Armakola M., Geser F., Greene R., Lu M.M., Padmanabhan A., Clay-Falcone D.,
RA   McCluskey L., Elman L., Juhr D., Gruber P.J., Rub U., Auburger G.,
RA   Trojanowski J.Q., Lee V.M., Van Deerlin V.M., Bonini N.M., Gitler A.D.;
RT   "Ataxin-2 intermediate-length polyglutamine expansions are associated with
RT   increased risk for ALS.";
RL   Nature 466:1069-1075(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   FUNCTION.
RX   PubMed=21358640; DOI=10.1038/nn.2778;
RA   Tollervey J.R., Curk T., Rogelj B., Briese M., Cereda M., Kayikci M.,
RA   Koenig J., Hortobagyi T., Nishimura A.L., Zupunski V., Patani R.,
RA   Chandran S., Rot G., Zupan B., Shaw C.E., Ule J.;
RT   "Characterizing the RNA targets and position-dependent splicing regulation
RT   by TDP-43.";
RL   Nat. Neurosci. 14:452-458(2011).
RN   [22]
RP   FUNCTION, AND RNA-BINDING.
RX   PubMed=23519609; DOI=10.1093/nar/gkt189;
RA   Bhardwaj A., Myers M.P., Buratti E., Baralle F.E.;
RT   "Characterizing TDP-43 interaction with its RNA targets.";
RL   Nucleic Acids Res. 41:5062-5074(2013).
RN   [23]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=23398327; DOI=10.1111/jnc.12194;
RA   Higashi S., Kabuta T., Nagai Y., Tsuchiya Y., Akiyama H., Wada K.;
RT   "TDP-43 associates with stalled ribosomes and contributes to cell survival
RT   during cellular stress.";
RL   J. Neurochem. 126:288-300(2013).
RN   [24]
RP   INTERACTION WITH UBQLN2.
RX   PubMed=23541532; DOI=10.1016/j.bbapap.2013.03.020;
RA   Cassel J.A., Reitz A.B.;
RT   "Ubiquilin-2 (UBQLN2) binds with high affinity to the C-terminal region of
RT   TDP-43 and modulates TDP-43 levels in H4 cells: characterization of
RT   inhibition by nucleic acids and 4-aminoquinolines.";
RL   Biochim. Biophys. Acta 1834:964-971(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-183 AND SER-292, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-293, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [28]
RP   INTERACTION WITH MATR3.
RX   PubMed=24686783; DOI=10.1038/nn.3688;
RA   Johnson J.O., Pioro E.P., Boehringer A., Chia R., Feit H., Renton A.E.,
RA   Pliner H.A., Abramzon Y., Marangi G., Winborn B.J., Gibbs J.R., Nalls M.A.,
RA   Morgan S., Shoai M., Hardy J., Pittman A., Orrell R.W., Malaspina A.,
RA   Sidle K.C., Fratta P., Harms M.B., Baloh R.H., Pestronk A., Weihl C.C.,
RA   Rogaeva E., Zinman L., Drory V.E., Borghero G., Mora G., Calvo A.,
RA   Rothstein J.D., Drepper C., Sendtner M., Singleton A.B., Taylor J.P.,
RA   Cookson M.R., Restagno G., Sabatelli M., Bowser R., Chio A., Traynor B.J.;
RT   "Mutations in the matrin 3 gene cause familial amyotrophic lateral
RT   sclerosis.";
RL   Nat. Neurosci. 17:664-666(2014).
RN   [29]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-181, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [30]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-102 AND LYS-181, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [31]
RP   FUNCTION, AND INTERACTION WITH CRY2.
RX   PubMed=27123980; DOI=10.1371/journal.pone.0154263;
RA   Hirano A., Nakagawa T., Yoshitane H., Oyama M., Kozuka-Hata H.,
RA   Lanjakornsiripan D., Fukada Y.;
RT   "USP7 and TDP-43: pleiotropic regulation of cryptochrome protein stability
RT   paces the oscillation of the mammalian circadian clock.";
RL   PLoS ONE 11:E0154263-E0154263(2016).
RN   [32]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-79; LYS-84; LYS-95; LYS-181 AND
RP   LYS-263, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [33]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=28794432; DOI=10.1038/s41598-017-06953-y;
RA   Izumikawa K., Nobe Y., Yoshikawa H., Ishikawa H., Miura Y., Nakayama H.,
RA   Nonaka T., Hasegawa M., Egawa N., Inoue H., Nishikawa K., Yamano K.,
RA   Simpson R.J., Taoka M., Yamauchi Y., Isobe T., Takahashi N.;
RT   "TDP-43 stabilises the processing intermediates of mitochondrial
RT   transcripts.";
RL   Sci. Rep. 7:7709-7709(2017).
RN   [34]
RP   FUNCTION, AND INTERACTION WITH CNOT7.
RX   PubMed=30520513; DOI=10.1002/1873-3468.13310;
RA   Fukushima M., Hosoda N., Chifu K., Hoshino S.I.;
RT   "TDP-43 accelerates deadenylation of target mRNAs by recruiting Caf1
RT   deadenylase.";
RL   FEBS Lett. 593:277-287(2019).
RN   [35]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=30464263; DOI=10.1038/s41586-018-0665-2;
RA   Vogler T.O., Wheeler J.R., Nguyen E.D., Hughes M.P., Britson K.A.,
RA   Lester E., Rao B., Betta N.D., Whitney O.N., Ewachiw T.E., Gomes E.,
RA   Shorter J., Lloyd T.E., Eisenberg D.S., Taylor J.P., Johnson A.M.,
RA   Olwin B.B., Parker R.;
RT   "TDP-43 and RNA form amyloid-like myo-granules in regenerating muscle.";
RL   Nature 563:508-513(2018).
RN   [36]
RP   STRUCTURE BY NMR OF 96-267.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the RNA binding domains of TAR DNA-binding protein-
RT   43.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [37]
RP   STRUCTURE BY NMR OF 193-267.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of RRM domain in tar DNA-binding protein-43.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [38]
RP   STRUCTURE BY NMR OF 102-269, RNA-BINDING, AND FUNCTION.
RX   PubMed=24240615; DOI=10.1038/nsmb.2698;
RA   Lukavsky P.J., Daujotyte D., Tollervey J.R., Ule J., Stuani C., Buratti E.,
RA   Baralle F.E., Damberger F.F., Allain F.H.;
RT   "Molecular basis of UG-rich RNA recognition by the human splicing factor
RT   TDP-43.";
RL   Nat. Struct. Mol. Biol. 20:1443-1449(2013).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 103-179, FUNCTION, AND SUBUNIT.
RX   PubMed=24464995; DOI=10.1093/nar/gkt1407;
RA   Kuo P.H., Chiang C.H., Wang Y.T., Doudeva L.G., Yuan H.S.;
RT   "The crystal structure of TDP-43 RRM1-DNA complex reveals the specific
RT   recognition for UG- and TG-rich nucleic acids.";
RL   Nucleic Acids Res. 42:4712-4722(2014).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 2-80, SUBUNIT, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=28663553; DOI=10.1038/s41467-017-00062-0;
RA   Afroz T., Hock E.M., Ernst P., Foglieni C., Jambeau M., Gilhespy L.A.B.,
RA   Laferriere F., Maniecka Z., Plueckthun A., Mittl P., Paganetti P.,
RA   Allain F.H.T., Polymenidou M.;
RT   "Functional and dynamic polymerization of the ALS-linked protein TDP-43
RT   antagonizes its pathologic aggregation.";
RL   Nat. Commun. 8:45-45(2017).
RN   [41]
RP   STRUCTURE BY NMR OF 1-80, MUTAGENESIS OF SER-48, SUBUNIT, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=29438978; DOI=10.15252/embj.201797452;
RA   Wang A., Conicella A.E., Schmidt H.B., Martin E.W., Rhoads S.N., Reeb A.N.,
RA   Nourse A., Ramirez Montero D., Ryan V.H., Rohatgi R., Shewmaker F.,
RA   Naik M.T., Mittag T., Ayala Y.M., Fawzi N.L.;
RT   "A single N-terminal phosphomimic disrupts TDP-43 polymerization, phase
RT   separation, and RNA splicing.";
RL   EMBO J. 37:0-0(2018).
RN   [42]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.40 ANGSTROMS) OF 247-257.
RX   PubMed=29531287; DOI=10.1038/s41594-018-0045-5;
RA   Guenther E.L., Ge P., Trinh H., Sawaya M.R., Cascio D., Boyer D.R.,
RA   Gonen T., Zhou Z.H., Eisenberg D.S.;
RT   "Atomic-level evidence for packing and positional amyloid polymorphism by
RT   segment from TDP-43 RRM2.";
RL   Nat. Struct. Mol. Biol. 25:311-319(2018).
RN   [43]
RP   VARIANT ALS10 THR-315.
RX   PubMed=18288693; DOI=10.1002/ana.21344;
RA   Gitcho M.A., Baloh R.H., Chakraverty S., Mayo K., Norton J.B., Levitch D.,
RA   Hatanpaa K.J., White C.L. III, Bigio E.H., Caselli R., Baker M.,
RA   Al-Lozi M.T., Morris J.C., Pestronk A., Rademakers R., Goate A.M.,
RA   Cairns N.J.;
RT   "TDP-43 A315T mutation in familial motor neuron disease.";
RL   Ann. Neurol. 63:535-538(2008).
RN   [44]
RP   VARIANT ALS10 ARG-343.
RX   PubMed=18438952; DOI=10.1002/ana.21392;
RA   Yokoseki A., Shiga A., Tan C.F., Tagawa A., Kaneko H., Koyama A.,
RA   Eguchi H., Tsujino A., Ikeuchi T., Kakita A., Okamoto K., Nishizawa M.,
RA   Takahashi H., Onodera O.;
RT   "TDP-43 mutation in familial amyotrophic lateral sclerosis.";
RL   Ann. Neurol. 63:538-542(2008).
RN   [45]
RP   VARIANTS ALS10 ALA-290 AND SER-298.
RX   PubMed=18396105; DOI=10.1016/s1474-4422(08)70071-1;
RA   Van Deerlin V.M., Leverenz J.B., Bekris L.M., Bird T.D., Yuan W.,
RA   Elman L.B., Clay D., Wood E.M., Chen-Plotkin A.S., Martinez-Lage M.,
RA   Steinbart E., McCluskey L., Grossman M., Neumann M., Wu I.-L., Yang W.-S.,
RA   Kalb R., Galasko D.R., Montine T.J., Trojanowski J.Q., Lee V.M.-Y.,
RA   Schellenberg G.D., Yu C.-E.;
RT   "TARDBP mutations in amyotrophic lateral sclerosis with TDP-43
RT   neuropathology: a genetic and histopathological analysis.";
RL   Lancet Neurol. 7:409-416(2008).
RN   [46]
RP   VARIANTS ALS10 GLY-169; SER-287; THR-315; CYS-348; SER-361; THR-382;
RP   ASP-390 AND SER-390, AND VARIANT VAL-90.
RX   PubMed=18372902; DOI=10.1038/ng.132;
RA   Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., McConkey B.J.,
RA   Vande Velde C., Bouchard J.-P., Lacomblez L., Pochigaeva K., Salachas F.,
RA   Pradat P.-F., Camu W., Meininger V., Dupre N., Rouleau G.A.;
RT   "TARDBP mutations in individuals with sporadic and familial amyotrophic
RT   lateral sclerosis.";
RL   Nat. Genet. 40:572-574(2008).
RN   [47]
RP   VARIANTS ALS10 ALA-294; LYS-331 AND VAL-337, VARIANT VAL-90, AND
RP   CHARACTERIZATION OF VARIANTS ALS10 LYS-331 AND VAL-337.
RX   PubMed=18309045; DOI=10.1126/science.1154584;
RA   Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B.,
RA   Ackerley S., Durnall J.C., Williams K.L., Buratti E., Baralle F.,
RA   de Belleroche J., Mitchell J.D., Leigh P.N., Al-Chalabi A., Miller C.C.,
RA   Nicholson G., Shaw C.E.;
RT   "TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis.";
RL   Science 319:1668-1672(2008).
RN   [48]
RP   INVOLVEMENT OF VARIANT ALS10 SER-295 IN FRONTOTEMPORAL LOBAR DEGENERATION
RP   WITH MOTOR NEURON DISEASE.
RX   PubMed=19350673; DOI=10.1002/ana.21612;
RG   French clinical and genetic research network on frontotemporal lobar degeneration/frontotemporal lobar degeneration with motoneuron disease;
RA   Benajiba L., Le Ber I., Camuzat A., Lacoste M., Thomas-Anterion C.,
RA   Couratier P., Legallic S., Salachas F., Hannequin D., Decousus M.,
RA   Lacomblez L., Guedj E., Golfier V., Camu W., Dubois B., Campion D.,
RA   Meininger V., Brice A.;
RT   "TARDBP mutations in motoneuron disease with frontotemporal lobar
RT   degeneration.";
RL   Ann. Neurol. 65:470-473(2009).
RN   [49]
RP   VARIANTS ALS10 SER-267; SER-287; VAL-294; SER-295; ARG-295; ASN-332;
RP   ASP-335; VAL-337; PRO-379; CYS-379; THR-382 AND LEU-393.
RX   PubMed=19224587; DOI=10.1002/humu.20950;
RA   Corrado L., Ratti A., Gellera C., Buratti E., Castellotti B.,
RA   Carlomagno Y., Ticozzi N., Mazzini L., Testa L., Taroni F., Baralle F.E.,
RA   Silani V., D'Alfonso S.;
RT   "High frequency of TARDBP gene mutations in Italian patients with
RT   amyotrophic lateral sclerosis.";
RL   Hum. Mutat. 30:688-694(2009).
RN   [50]
RP   INVOLVEMENT OF VARIANT ALS10 SER-267 IN FRONTOTEMPORAL DEMENTIA.
RX   PubMed=19655382; DOI=10.1002/humu.21100;
RA   Borroni B., Bonvicini C., Alberici A., Buratti E., Agosti C., Archetti S.,
RA   Papetti A., Stuani C., Di Luca M., Gennarelli M., Padovani A.;
RT   "Mutation within TARDBP leads to frontotemporal dementia without motor
RT   neuron disease.";
RL   Hum. Mutat. 30:E974-E983(2009).
RN   [51]
RP   VARIANT ALS10 ALA-294.
RX   PubMed=19695877; DOI=10.1016/j.nmd.2009.07.005;
RA   Luquin N., Yu B., Saunderson R.B., Trent R.J., Pamphlett R.;
RT   "Genetic variants in the promoter of TARDBP in sporadic amyotrophic lateral
RT   sclerosis.";
RL   Neuromuscul. Disord. 19:696-700(2009).
RN   [52]
RP   VARIANTS ALS10 SER-287; VAL-321; VAL-337 AND VAL-348, VARIANT VAL-90,
RP   CHARACTERIZATION OF VARIANTS ALS10 SER-287; VAL-321 AND VAL-337, AND
RP   FUNCTION.
RX   PubMed=19760257; DOI=10.1007/s10048-009-0218-9;
RA   Kirby J., Goodall E.F., Smith W., Highley J.R., Masanzu R., Hartley J.A.,
RA   Hibberd R., Hollinger H.C., Wharton S.B., Morrison K.E., Ince P.G.,
RA   McDermott C.J., Shaw P.J.;
RT   "Broad clinical phenotypes associated with TAR-DNA binding protein (TARDBP)
RT   mutations in amyotrophic lateral sclerosis.";
RL   Neurogenetics 11:217-225(2010).
RN   [53]
RP   VARIANT ALS10 THR-382.
RX   PubMed=21220647; DOI=10.1001/archneurol.2010.352;
RA   Chio A., Borghero G., Pugliatti M., Ticca A., Calvo A., Moglia C.,
RA   Mutani R., Brunetti M., Ossola I., Marrosu M.G., Murru M.R., Floris G.,
RA   Cannas A., Parish L.D., Cossu P., Abramzon Y., Johnson J.O., Nalls M.A.,
RA   Arepalli S., Chong S., Hernandez D.G., Traynor B.J., Restagno G.;
RT   "Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to
RT   a single founder mutation of the TARDBP gene.";
RL   Arch. Neurol. 68:594-598(2011).
RN   [54]
RP   VARIANT ALS10 THR-382.
RX   PubMed=21418058; DOI=10.1111/j.1399-0004.2011.01668.x;
RA   Orru S., Manolakos E., Orru N., Kokotas H., Mascia V., Carcassi C.,
RA   Petersen M.B.;
RT   "High frequency of the TARDBP p.Ala382Thr mutation in Sardinian patients
RT   with amyotrophic lateral sclerosis.";
RL   Clin. Genet. 81:172-178(2012).
RN   [55]
RP   VARIANT VAL-90, AND VARIANTS ALS10 ARG-357; THR-361 AND PRO-379.
RX   PubMed=22456481; DOI=10.1038/jhg.2012.24;
RA   Chiang H.H., Andersen P.M., Tysnes O.B., Gredal O., Christensen P.B.,
RA   Graff C.;
RT   "Novel TARDBP mutations in Nordic ALS patients.";
RL   J. Hum. Genet. 57:316-319(2012).
RN   [56]
RP   CHARACTERIZATION OF VARIANTS ALS10 VAL-348; THR-315 AND SER-361, FUNCTION,
RP   SUBCELLULAR LOCATION, INTERACTION WITH PPIA, AND MUTAGENESIS OF
RP   103-THR--SER-183.
RX   PubMed=25678563; DOI=10.1093/brain/awv005;
RA   Lauranzano E., Pozzi S., Pasetto L., Stucchi R., Massignan T., Paolella K.,
RA   Mombrini M., Nardo G., Lunetta C., Corbo M., Mora G., Bendotti C.,
RA   Bonetto V.;
RT   "Peptidylprolyl isomerase A governs TARDBP function and assembly in
RT   heterogeneous nuclear ribonucleoprotein complexes.";
RL   Brain 138:974-991(2015).
RN   [57]
RP   CHARACTERIZATION OF VARIANTS ALS10 THR-315 AND LYS-331, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=33031745; DOI=10.1016/j.cell.2020.09.020;
RA   Yu C.H., Davidson S., Harapas C.R., Hilton J.B., Mlodzianoski M.J.,
RA   Laohamonthonkul P., Louis C., Low R.R.J., Moecking J., De Nardo D.,
RA   Balka K.R., Calleja D.J., Moghaddas F., Ni E., McLean C.A., Samson A.L.,
RA   Tyebji S., Tonkin C.J., Bye C.R., Turner B.J., Pepin G., Gantier M.P.,
RA   Rogers K.L., McArthur K., Crouch P.J., Masters S.L.;
RT   "TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING
RT   in ALS.";
RL   Cell 183:636-649(2020).
CC   -!- FUNCTION: RNA-binding protein that is involved in various steps of RNA
CC       biogenesis and processing (PubMed:23519609). Preferentially binds, via
CC       its two RNA recognition motifs RRM1 and RRM2, to GU-repeats on RNA
CC       molecules predominantly localized within long introns and in the 3'UTR
CC       of mRNAs (PubMed:23519609, PubMed:24240615, PubMed:24464995). In turn,
CC       regulates the splicing of many non-coding and protein-coding RNAs
CC       including proteins involved in neuronal survival, as well as mRNAs that
CC       encode proteins relevant for neurodegenerative diseases
CC       (PubMed:21358640, PubMed:29438978). Plays a role in maintaining
CC       mitochondrial homeostasis by regulating the processing of mitochondrial
CC       transcripts (PubMed:28794432). Also regulates mRNA stability by
CC       recruiting CNOT7/CAF1 deadenylase on mRNA 3'UTR leading to poly(A) tail
CC       deadenylation and thus shortening (PubMed:30520513). In response to
CC       oxidative insult, associates with stalled ribosomes localized to stress
CC       granules (SGs) and contributes to cell survival (PubMed:19765185,
CC       PubMed:23398327). Also participates in the normal skeletal muscle
CC       formation and regeneration, forming cytoplasmic myo-granules and
CC       binding mRNAs that encode sarcomeric proteins (PubMed:30464263). Plays
CC       a role in the maintenance of the circadian clock periodicity via
CC       stabilization of the CRY1 and CRY2 proteins in a FBXL3-dependent manner
CC       (PubMed:27123980). Negatively regulates the expression of CDK6
CC       (PubMed:19760257). Regulates the expression of HDAC6, ATG7 and VCP in a
CC       PPIA/CYPA-dependent manner (PubMed:25678563).
CC       {ECO:0000269|PubMed:11285240, ECO:0000269|PubMed:17481916,
CC       ECO:0000269|PubMed:19760257, ECO:0000269|PubMed:19765185,
CC       ECO:0000269|PubMed:21358640, ECO:0000269|PubMed:23398327,
CC       ECO:0000269|PubMed:23519609, ECO:0000269|PubMed:24240615,
CC       ECO:0000269|PubMed:24464995, ECO:0000269|PubMed:25678563,
CC       ECO:0000269|PubMed:27123980, ECO:0000269|PubMed:28794432,
CC       ECO:0000269|PubMed:29438978, ECO:0000269|PubMed:30464263,
CC       ECO:0000269|PubMed:30520513}.
CC   -!- SUBUNIT: Homodimer (PubMed:20043239, PubMed:24464995). Homooligomer
CC       (via its N-terminal domain) (PubMed:28663553, PubMed:29438978).
CC       Interacts with BRDT (By similarity). Binds specifically to pyrimidine-
CC       rich motifs of TAR DNA and to single stranded TG repeated sequences.
CC       Binds to RNA, specifically to UG repeated sequences with a minimum of
CC       six contiguous repeats. Interacts with ATXN2; the interaction is RNA-
CC       dependent (PubMed:20740007). Interacts with MATR3 (PubMed:24686783).
CC       Interacts with UBQLN2 (PubMed:23541532). Interacts with HNRNPA2B1
CC       (PubMed:19429692). Interacts with ZNF106 (By similarity). Interacts
CC       with CNOT7/CAF1 (PubMed:30520513). Interacts with CRY2
CC       (PubMed:27123980). Interacts with PPIA/CYPA; the interaction is
CC       dependent on RNA-binding activity of TARDBP and PPIase activity of
CC       PPIA/CYPA and acetylation of PPIA/CYPA at 'Lys-125' favors the
CC       interaction (PubMed:25678563). {ECO:0000250|UniProtKB:Q921F2,
CC       ECO:0000269|PubMed:11470789, ECO:0000269|PubMed:19429692,
CC       ECO:0000269|PubMed:20043239, ECO:0000269|PubMed:20740007,
CC       ECO:0000269|PubMed:23541532, ECO:0000269|PubMed:24464995,
CC       ECO:0000269|PubMed:24686783, ECO:0000269|PubMed:25678563,
CC       ECO:0000269|PubMed:27123980, ECO:0000269|PubMed:28663553,
CC       ECO:0000269|PubMed:29438978, ECO:0000269|PubMed:30520513}.
CC   -!- INTERACTION:
CC       Q13148; Q969K4: ABTB1; NbExp=3; IntAct=EBI-372899, EBI-7223971;
CC       Q13148; P55265: ADAR; NbExp=3; IntAct=EBI-372899, EBI-2462104;
CC       Q13148; Q6ZTN6-2: ANKRD13D; NbExp=3; IntAct=EBI-372899, EBI-25840993;
CC       Q13148; P13928: ANXA8; NbExp=6; IntAct=EBI-372899, EBI-2556915;
CC       Q13148; P63010-2: AP2B1; NbExp=6; IntAct=EBI-372899, EBI-11529439;
CC       Q13148; P05067: APP; NbExp=6; IntAct=EBI-372899, EBI-77613;
CC       Q13148; P05067-2: APP; NbExp=3; IntAct=EBI-372899, EBI-17264467;
CC       Q13148; Q0P5N6: ARL16; NbExp=6; IntAct=EBI-372899, EBI-10186132;
CC       Q13148; Q8WXK3: ASB13; NbExp=3; IntAct=EBI-372899, EBI-707573;
CC       Q13148; Q9Y575-3: ASB3; NbExp=3; IntAct=EBI-372899, EBI-14199987;
CC       Q13148; Q96DX5: ASB9; NbExp=3; IntAct=EBI-372899, EBI-745641;
CC       Q13148; Q96DX5-3: ASB9; NbExp=3; IntAct=EBI-372899, EBI-25843552;
CC       Q13148; Q96FT7-4: ASIC4; NbExp=6; IntAct=EBI-372899, EBI-9089489;
CC       Q13148; P18847: ATF3; NbExp=6; IntAct=EBI-372899, EBI-712767;
CC       Q13148; O95352-2: ATG7; NbExp=3; IntAct=EBI-372899, EBI-15980880;
CC       Q13148; P15313: ATP6V1B1; NbExp=6; IntAct=EBI-372899, EBI-2891281;
CC       Q13148; Q99700: ATXN2; NbExp=3; IntAct=EBI-372899, EBI-697691;
CC       Q13148; P46379-2: BAG6; NbExp=6; IntAct=EBI-372899, EBI-10988864;
CC       Q13148; Q8TBE0: BAHD1; NbExp=6; IntAct=EBI-372899, EBI-742750;
CC       Q13148; Q5H9J7: BEX5; NbExp=6; IntAct=EBI-372899, EBI-10243741;
CC       Q13148; O15392: BIRC5; NbExp=6; IntAct=EBI-372899, EBI-518823;
CC       Q13148; Q9H0C5: BTBD1; NbExp=3; IntAct=EBI-372899, EBI-935503;
CC       Q13148; Q5SZD1: C6orf141; NbExp=6; IntAct=EBI-372899, EBI-10697767;
CC       Q13148; Q96LL4: C8orf48; NbExp=6; IntAct=EBI-372899, EBI-751596;
CC       Q13148; Q13191: CBLB; NbExp=6; IntAct=EBI-372899, EBI-744027;
CC       Q13148; Q9ULV8: CBLC; NbExp=3; IntAct=EBI-372899, EBI-2341018;
CC       Q13148; Q14781-2: CBX2; NbExp=6; IntAct=EBI-372899, EBI-11974585;
CC       Q13148; Q13939: CCIN; NbExp=3; IntAct=EBI-372899, EBI-25879469;
CC       Q13148; Q13042: CDC16; NbExp=3; IntAct=EBI-372899, EBI-994830;
CC       Q13148; Q13042-2: CDC16; NbExp=3; IntAct=EBI-372899, EBI-10974085;
CC       Q13148; Q9UJX2: CDC23; NbExp=3; IntAct=EBI-372899, EBI-396137;
CC       Q13148; Q92879-3: CELF1; NbExp=3; IntAct=EBI-372899, EBI-21370617;
CC       Q13148; Q8NHQ1-3: CEP70; NbExp=6; IntAct=EBI-372899, EBI-11526150;
CC       Q13148; Q494V2-2: CFAP100; NbExp=6; IntAct=EBI-372899, EBI-11953200;
CC       Q13148; O14647: CHD2; NbExp=2; IntAct=EBI-372899, EBI-1210503;
CC       Q13148; Q16740: CLPP; NbExp=3; IntAct=EBI-372899, EBI-1056029;
CC       Q13148; Q8IUI8: CRLF3; NbExp=6; IntAct=EBI-372899, EBI-2872414;
CC       Q13148; P48730-2: CSNK1D; NbExp=6; IntAct=EBI-372899, EBI-9087876;
CC       Q13148; P61962: DCAF7; NbExp=3; IntAct=EBI-372899, EBI-359808;
CC       Q13148; Q5TAQ9-2: DCAF8; NbExp=6; IntAct=EBI-372899, EBI-25842815;
CC       Q13148; Q5TDH0-2: DDI2; NbExp=3; IntAct=EBI-372899, EBI-25858598;
CC       Q13148; Q92841: DDX17; NbExp=6; IntAct=EBI-372899, EBI-746012;
CC       Q13148; O00571: DDX3X; NbExp=6; IntAct=EBI-372899, EBI-353779;
CC       Q13148; P17844: DDX5; NbExp=3; IntAct=EBI-372899, EBI-351962;
CC       Q13148; O75398: DEAF1; NbExp=3; IntAct=EBI-372899, EBI-718185;
CC       Q13148; Q96EY1-3: DNAJA3; NbExp=6; IntAct=EBI-372899, EBI-11526226;
CC       Q13148; Q92782-2: DPF1; NbExp=6; IntAct=EBI-372899, EBI-23669343;
CC       Q13148; Q86TI2-2: DPP9; NbExp=6; IntAct=EBI-372899, EBI-21529239;
CC       Q13148; O75530-2: EED; NbExp=3; IntAct=EBI-372899, EBI-11132357;
CC       Q13148; O00303: EIF3F; NbExp=6; IntAct=EBI-372899, EBI-711990;
CC       Q13148; Q15717: ELAVL1; NbExp=7; IntAct=EBI-372899, EBI-374260;
CC       Q13148; Q8TC29: ENKUR; NbExp=6; IntAct=EBI-372899, EBI-9246952;
CC       Q13148; P29323-3: EPHB2; NbExp=6; IntAct=EBI-372899, EBI-25838727;
CC       Q13148; Q6NXG1: ESRP1; NbExp=6; IntAct=EBI-372899, EBI-10213520;
CC       Q13148; O00471: EXOC5; NbExp=6; IntAct=EBI-372899, EBI-949824;
CC       Q13148; Q6P1L5: FAM117B; NbExp=6; IntAct=EBI-372899, EBI-3893327;
CC       Q13148; Q17RN3: FAM98C; NbExp=6; IntAct=EBI-372899, EBI-5461838;
CC       Q13148; Q8IZU1: FAM9A; NbExp=6; IntAct=EBI-372899, EBI-8468186;
CC       Q13148; Q9UKA1: FBXL5; NbExp=3; IntAct=EBI-372899, EBI-2692340;
CC       Q13148; Q9UKT5: FBXO4; NbExp=3; IntAct=EBI-372899, EBI-960409;
CC       Q13148; P35637: FUS; NbExp=9; IntAct=EBI-372899, EBI-400434;
CC       Q13148; Q06547-2: GABPB1; NbExp=6; IntAct=EBI-372899, EBI-618189;
CC       Q13148; Q96IJ6: GMPPA; NbExp=6; IntAct=EBI-372899, EBI-750953;
CC       Q13148; P62879: GNB2; NbExp=7; IntAct=EBI-372899, EBI-356942;
CC       Q13148; Q9Y4H4: GPSM3; NbExp=6; IntAct=EBI-372899, EBI-347538;
CC       Q13148; Q969Y2: GTPBP3; NbExp=6; IntAct=EBI-372899, EBI-740290;
CC       Q13148; Q9UBN7: HDAC6; NbExp=3; IntAct=EBI-372899, EBI-301697;
CC       Q13148; Q9HCC6: HES4; NbExp=6; IntAct=EBI-372899, EBI-2680288;
CC       Q13148; P07910: HNRNPC; NbExp=3; IntAct=EBI-372899, EBI-357966;
CC       Q13148; P07910-2: HNRNPC; NbExp=6; IntAct=EBI-372899, EBI-5280084;
CC       Q13148; O14979: HNRNPDL; NbExp=3; IntAct=EBI-372899, EBI-299727;
CC       Q13148; P31943: HNRNPH1; NbExp=7; IntAct=EBI-372899, EBI-351590;
CC       Q13148; P61978: HNRNPK; NbExp=3; IntAct=EBI-372899, EBI-304185;
CC       Q13148; P61978-2: HNRNPK; NbExp=6; IntAct=EBI-372899, EBI-7060731;
CC       Q13148; O43390-2: HNRNPR; NbExp=3; IntAct=EBI-372899, EBI-12236340;
CC       Q13148; Q00839-2: HNRNPU; NbExp=6; IntAct=EBI-372899, EBI-351143;
CC       Q13148; Q9BUJ2: HNRNPUL1; NbExp=3; IntAct=EBI-372899, EBI-1018153;
CC       Q13148; Q9BUJ2-2: HNRNPUL1; NbExp=3; IntAct=EBI-372899, EBI-11018029;
CC       Q13148; Q9BTB7: HNRPUL1; NbExp=3; IntAct=EBI-372899, EBI-10298318;
CC       Q13148; Q02363: ID2; NbExp=6; IntAct=EBI-372899, EBI-713450;
CC       Q13148; P80217-2: IFI35; NbExp=6; IntAct=EBI-372899, EBI-12823003;
CC       Q13148; Q9Y6M1: IGF2BP2; NbExp=3; IntAct=EBI-372899, EBI-1024419;
CC       Q13148; O00425: IGF2BP3; NbExp=6; IntAct=EBI-372899, EBI-1058566;
CC       Q13148; Q12906-6: ILF3; NbExp=6; IntAct=EBI-372899, EBI-12904528;
CC       Q13148; Q9NXX0: ILF3; NbExp=3; IntAct=EBI-372899, EBI-743980;
CC       Q13148; Q6DN90-2: IQSEC1; NbExp=6; IntAct=EBI-372899, EBI-21911304;
CC       Q13148; O43187: IRAK2; NbExp=2; IntAct=EBI-372899, EBI-447733;
CC       Q13148; Q92613: JADE3; NbExp=6; IntAct=EBI-372899, EBI-10278909;
CC       Q13148; Q9NVX7-2: KBTBD4; NbExp=6; IntAct=EBI-372899, EBI-25871195;
CC       Q13148; Q96SI1-2: KCTD15; NbExp=6; IntAct=EBI-372899, EBI-12382297;
CC       Q13148; Q8N5Z5: KCTD17; NbExp=6; IntAct=EBI-372899, EBI-743960;
CC       Q13148; Q9UIH9: KLF15; NbExp=6; IntAct=EBI-372899, EBI-2796400;
CC       Q13148; Q6TDP4: KLHL17; NbExp=3; IntAct=EBI-372899, EBI-21328926;
CC       Q13148; Q9Y2M5: KLHL20; NbExp=3; IntAct=EBI-372899, EBI-714379;
CC       Q13148; Q53GT1: KLHL22; NbExp=4; IntAct=EBI-372899, EBI-1996072;
CC       Q13148; Q53HC5: KLHL26; NbExp=3; IntAct=EBI-372899, EBI-724915;
CC       Q13148; Q96NJ5: KLHL32; NbExp=3; IntAct=EBI-372899, EBI-6426390;
CC       Q13148; Q8N4N3-2: KLHL36; NbExp=6; IntAct=EBI-372899, EBI-10973851;
CC       Q13148; O00629: KPNA4; NbExp=3; IntAct=EBI-372899, EBI-396343;
CC       Q13148; Q9BYQ4: KRTAP9-2; NbExp=6; IntAct=EBI-372899, EBI-1044640;
CC       Q13148; Q96JM7-2: L3MBTL3; NbExp=6; IntAct=EBI-372899, EBI-11985629;
CC       Q13148; Q9BYZ2: LDHAL6B; NbExp=6; IntAct=EBI-372899, EBI-1108377;
CC       Q13148; Q6DKI2: LGALS9C; NbExp=6; IntAct=EBI-372899, EBI-9088829;
CC       Q13148; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-372899, EBI-739832;
CC       Q13148; Q8N448: LNX2; NbExp=6; IntAct=EBI-372899, EBI-2340947;
CC       Q13148; Q1L5Z9: LONRF2; NbExp=3; IntAct=EBI-372899, EBI-2510853;
CC       Q13148; O95777: LSM8; NbExp=6; IntAct=EBI-372899, EBI-347779;
CC       Q13148; Q8TD91-2: MAGEC3; NbExp=6; IntAct=EBI-372899, EBI-10694180;
CC       Q13148; Q15759: MAPK11; NbExp=6; IntAct=EBI-372899, EBI-298304;
CC       Q13148; P43243: MATR3; NbExp=6; IntAct=EBI-372899, EBI-352602;
CC       Q13148; A0JLT2-2: MED19; NbExp=3; IntAct=EBI-372899, EBI-13288755;
CC       Q13148; Q8N6F8: METTL27; NbExp=6; IntAct=EBI-372899, EBI-8487781;
CC       Q13148; Q8TDB4: MGARP; NbExp=6; IntAct=EBI-372899, EBI-4397720;
CC       Q13148; Q8N108-16: MIER1; NbExp=6; IntAct=EBI-372899, EBI-25830642;
CC       Q13148; A4FUJ8: MKL1; NbExp=6; IntAct=EBI-372899, EBI-21250407;
CC       Q13148; Q9H000: MKRN2; NbExp=6; IntAct=EBI-372899, EBI-2341005;
CC       Q13148; Q13064: MKRN3; NbExp=3; IntAct=EBI-372899, EBI-2340269;
CC       Q13148; Q15049: MLC1; NbExp=6; IntAct=EBI-372899, EBI-8475277;
CC       Q13148; P51948: MNAT1; NbExp=3; IntAct=EBI-372899, EBI-716139;
CC       Q13148; O95396: MOCS3; NbExp=3; IntAct=EBI-372899, EBI-373206;
CC       Q13148; Q8N594: MPND; NbExp=6; IntAct=EBI-372899, EBI-2512452;
CC       Q13148; Q9Y483-4: MTF2; NbExp=3; IntAct=EBI-372899, EBI-10698053;
CC       Q13148; P01106: MYC; NbExp=6; IntAct=EBI-372899, EBI-447544;
CC       Q13148; O00746: NME4; NbExp=6; IntAct=EBI-372899, EBI-744871;
CC       Q13148; Q9UNZ2: NSFL1C; NbExp=4; IntAct=EBI-372899, EBI-721577;
CC       Q13148; Q8NFH3: NUP43; NbExp=3; IntAct=EBI-372899, EBI-1059321;
CC       Q13148; O15381-5: NVL; NbExp=6; IntAct=EBI-372899, EBI-18577082;
CC       Q13148; Q96FW1: OTUB1; NbExp=8; IntAct=EBI-372899, EBI-1058491;
CC       Q13148; Q6GQQ9-2: OTUD7B; NbExp=6; IntAct=EBI-372899, EBI-25830200;
CC       Q13148; P32242: OTX1; NbExp=6; IntAct=EBI-372899, EBI-740446;
CC       Q13148; Q6VY07: PACS1; NbExp=6; IntAct=EBI-372899, EBI-2555014;
CC       Q13148; Q9NR21-5: PARP11; NbExp=3; IntAct=EBI-372899, EBI-17159452;
CC       Q13148; Q9HBE1-4: PATZ1; NbExp=3; IntAct=EBI-372899, EBI-11022007;
CC       Q13148; Q9BYU1: PBX4; NbExp=6; IntAct=EBI-372899, EBI-10302990;
CC       Q13148; Q9NV79: PCMTD2; NbExp=3; IntAct=EBI-372899, EBI-6309018;
CC       Q13148; Q6ZMN7-2: PDZRN4; NbExp=3; IntAct=EBI-372899, EBI-25984441;
CC       Q13148; P09565: PP9974; NbExp=6; IntAct=EBI-372899, EBI-10196507;
CC       Q13148; O75807: PPP1R15A; NbExp=10; IntAct=EBI-372899, EBI-714746;
CC       Q13148; Q6ZMI0-5: PPP1R21; NbExp=6; IntAct=EBI-372899, EBI-25835994;
CC       Q13148; O60260-5: PRKN; NbExp=3; IntAct=EBI-372899, EBI-21251460;
CC       Q13148; Q6P2Q9: PRPF8; NbExp=3; IntAct=EBI-372899, EBI-538479;
CC       Q13148; P60891: PRPS1; NbExp=6; IntAct=EBI-372899, EBI-749195;
CC       Q13148; P28070: PSMB4; NbExp=3; IntAct=EBI-372899, EBI-603350;
CC       Q13148; P28062-2: PSMB8; NbExp=6; IntAct=EBI-372899, EBI-372312;
CC       Q13148; Q13200: PSMD2; NbExp=3; IntAct=EBI-372899, EBI-357648;
CC       Q13148; P26599-3: PTBP1; NbExp=3; IntAct=EBI-372899, EBI-16437588;
CC       Q13148; Q9NS91: RAD18; NbExp=3; IntAct=EBI-372899, EBI-2339393;
CC       Q13148; Q09028: RBBP4; NbExp=6; IntAct=EBI-372899, EBI-620823;
CC       Q13148; Q9BYM8: RBCK1; NbExp=3; IntAct=EBI-372899, EBI-2340624;
CC       Q13148; P98175: RBM10; NbExp=3; IntAct=EBI-372899, EBI-721525;
CC       Q13148; Q8TBY0: RBM46; NbExp=3; IntAct=EBI-372899, EBI-12068216;
CC       Q13148; P38159: RBMX; NbExp=3; IntAct=EBI-372899, EBI-743526;
CC       Q13148; Q04206: RELA; NbExp=3; IntAct=EBI-372899, EBI-73886;
CC       Q13148; Q9H871: RMND5A; NbExp=3; IntAct=EBI-372899, EBI-2797992;
CC       Q13148; Q96G75: RMND5B; NbExp=3; IntAct=EBI-372899, EBI-745055;
CC       Q13148; Q8N5U6: RNF10; NbExp=3; IntAct=EBI-372899, EBI-714023;
CC       Q13148; Q9ULX5: RNF112; NbExp=6; IntAct=EBI-372899, EBI-25829984;
CC       Q13148; Q8WVD3: RNF138; NbExp=3; IntAct=EBI-372899, EBI-749039;
CC       Q13148; Q9UBS8: RNF14; NbExp=3; IntAct=EBI-372899, EBI-2130308;
CC       Q13148; Q96A37: RNF166; NbExp=3; IntAct=EBI-372899, EBI-2130320;
CC       Q13148; Q96D59: RNF183; NbExp=3; IntAct=EBI-372899, EBI-743938;
CC       Q13148; Q8N488: RYBP; NbExp=6; IntAct=EBI-372899, EBI-752324;
CC       Q13148; Q15393: SF3B3; NbExp=6; IntAct=EBI-372899, EBI-346977;
CC       Q13148; Q8IUQ4-2: SIAH1; NbExp=3; IntAct=EBI-372899, EBI-11522811;
CC       Q13148; Q9GZS3: SKIC8; NbExp=6; IntAct=EBI-372899, EBI-358545;
CC       Q13148; Q8NCS7: SLC44A5; NbExp=6; IntAct=EBI-372899, EBI-21504521;
CC       Q13148; Q96GM5: SMARCD1; NbExp=6; IntAct=EBI-372899, EBI-358489;
CC       Q13148; Q9HCE7-2: SMURF1; NbExp=3; IntAct=EBI-372899, EBI-9845742;
CC       Q13148; O14544: SOCS6; NbExp=3; IntAct=EBI-372899, EBI-3929549;
CC       Q13148; Q99932-2: SPAG8; NbExp=6; IntAct=EBI-372899, EBI-11959123;
CC       Q13148; Q8NHS9: SPATA22; NbExp=6; IntAct=EBI-372899, EBI-7067260;
CC       Q13148; Q96BD6: SPSB1; NbExp=3; IntAct=EBI-372899, EBI-2659201;
CC       Q13148; O95630: STAMBP; NbExp=3; IntAct=EBI-372899, EBI-396676;
CC       Q13148; Q92797-2: SYMPK; NbExp=6; IntAct=EBI-372899, EBI-21560407;
CC       Q13148; O60506-4: SYNCRIP; NbExp=6; IntAct=EBI-372899, EBI-11123832;
CC       Q13148; Q13148: TARDBP; NbExp=31; IntAct=EBI-372899, EBI-372899;
CC       Q13148; Q5VWN6: TASOR2; NbExp=6; IntAct=EBI-372899, EBI-745958;
CC       Q13148; Q9Y458: TBX22; NbExp=6; IntAct=EBI-372899, EBI-6427217;
CC       Q13148; Q15554-4: TERF2; NbExp=6; IntAct=EBI-372899, EBI-25840535;
CC       Q13148; Q8WTV1: THAP3; NbExp=6; IntAct=EBI-372899, EBI-17438286;
CC       Q13148; Q92956-2: TNFRSF14; NbExp=6; IntAct=EBI-372899, EBI-25985089;
CC       Q13148; P50616: TOB1; NbExp=4; IntAct=EBI-372899, EBI-723281;
CC       Q13148; P36406: TRIM23; NbExp=3; IntAct=EBI-372899, EBI-740098;
CC       Q13148; Q9H8W5-2: TRIM45; NbExp=3; IntAct=EBI-372899, EBI-11993364;
CC       Q13148; L8E9Q5: TRIM65; NbExp=3; IntAct=EBI-372899, EBI-25843781;
CC       Q13148; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-372899, EBI-11525489;
CC       Q13148; Q86UV6-2: TRIM74; NbExp=3; IntAct=EBI-372899, EBI-10259086;
CC       Q13148; Q9BZR9: TRIM8; NbExp=3; IntAct=EBI-372899, EBI-2340370;
CC       Q13148; Q9C026: TRIM9; NbExp=6; IntAct=EBI-372899, EBI-720828;
CC       Q13148; P41226: UBA7; NbExp=3; IntAct=EBI-372899, EBI-751921;
CC       Q13148; Q13404: UBE2V1; NbExp=3; IntAct=EBI-372899, EBI-1050671;
CC       Q13148; O94941: UBOX5; NbExp=3; IntAct=EBI-372899, EBI-751901;
CC       Q13148; Q8IYU4: UBQLNL; NbExp=3; IntAct=EBI-372899, EBI-12295223;
CC       Q13148; Q92995: USP13; NbExp=3; IntAct=EBI-372899, EBI-714351;
CC       Q13148; O75604-3: USP2; NbExp=6; IntAct=EBI-372899, EBI-10696113;
CC       Q13148; Q86UV5: USP48; NbExp=3; IntAct=EBI-372899, EBI-2512161;
CC       Q13148; P40337-2: VHL; NbExp=3; IntAct=EBI-372899, EBI-12157263;
CC       Q13148; Q8NEZ2: VPS37A; NbExp=3; IntAct=EBI-372899, EBI-2850578;
CC       Q13148; Q8NEZ2-2: VPS37A; NbExp=3; IntAct=EBI-372899, EBI-10270911;
CC       Q13148; P58304: VSX2; NbExp=6; IntAct=EBI-372899, EBI-6427899;
CC       Q13148; Q9GZL7: WDR12; NbExp=3; IntAct=EBI-372899, EBI-2490660;
CC       Q13148; Q9BRX9: WDR83; NbExp=6; IntAct=EBI-372899, EBI-7705033;
CC       Q13148; O00308: WWP2; NbExp=3; IntAct=EBI-372899, EBI-743923;
CC       Q13148; Q9H0D6: XRN2; NbExp=7; IntAct=EBI-372899, EBI-372110;
CC       Q13148; P67809: YBX1; NbExp=6; IntAct=EBI-372899, EBI-354065;
CC       Q13148; O43167-2: ZBTB24; NbExp=3; IntAct=EBI-372899, EBI-25842419;
CC       Q13148; P24278: ZBTB25; NbExp=3; IntAct=EBI-372899, EBI-739899;
CC       Q13148; Q8N895: ZNF366; NbExp=4; IntAct=EBI-372899, EBI-2813661;
CC       Q13148; Q9P0T4: ZNF581; NbExp=6; IntAct=EBI-372899, EBI-745520;
CC       Q13148; Q8NBB4-2: ZSCAN1; NbExp=6; IntAct=EBI-372899, EBI-12021938;
CC       Q13148; A0A384ME25; NbExp=6; IntAct=EBI-372899, EBI-10211777;
CC       Q13148; Q9H669; NbExp=6; IntAct=EBI-372899, EBI-10307430;
CC       Q13148; Q9WMX2; Xeno; NbExp=2; IntAct=EBI-372899, EBI-710918;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17023659,
CC       ECO:0000269|PubMed:17481916, ECO:0000269|PubMed:18957508,
CC       ECO:0000269|PubMed:19765185, ECO:0000269|PubMed:25678563,
CC       ECO:0000269|PubMed:28663553, ECO:0000269|PubMed:29438978}. Cytoplasm
CC       {ECO:0000269|PubMed:18957508, ECO:0000269|PubMed:23398327,
CC       ECO:0000269|PubMed:30464263}. Cytoplasm, Stress granule
CC       {ECO:0000269|PubMed:19765185, ECO:0000269|PubMed:23398327}.
CC       Mitochondrion {ECO:0000269|PubMed:28794432,
CC       ECO:0000269|PubMed:33031745}. Note=Continuously travels in and out of
CC       the nucleus (PubMed:18957508). Localizes to stress granules in response
CC       to oxidative stress (PubMed:19765185). A small subset localizes in
CC       mitochondria (PubMed:28794432). {ECO:0000269|PubMed:18957508,
CC       ECO:0000269|PubMed:19765185, ECO:0000269|PubMed:28794432}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13148-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13148-4; Sequence=VSP_056406, VSP_056407;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. In particular, expression
CC       is high in pancreas, placenta, lung, genital tract and spleen.
CC   -!- DOMAIN: Consists of an N-terminal domain (NTD) and two tandem RNA
CC       recognition motifs, RRM1 and RRM2, followed by a C-terminal glycine-
CC       rich region.
CC   -!- DOMAIN: Contains a nuclear localization sequence and is mostly nuclear;
CC       however, its nuclear export sequence permits it to transport mRNAs to
CC       the cytoplasm and even to synapses as part of neuronal granules.
CC       {ECO:0000269|PubMed:18957508}.
CC   -!- PTM: Hyperphosphorylated in hippocampus, neocortex, and spinal cord
CC       from individuals affected with ALS and FTLDU. Phosphorylated upon
CC       cellular stress. {ECO:0000269|PubMed:23398327}.
CC   -!- PTM: Ubiquitinated in hippocampus, neocortex, and spinal cord from
CC       individuals affected with ALS and FTLDU. {ECO:0000269|PubMed:17023659,
CC       ECO:0000269|PubMed:17481916}.
CC   -!- PTM: Cleaved to generate C-terminal fragments in hippocampus,
CC       neocortex, and spinal cord from individuals affected with ALS and
CC       FTLDU.
CC   -!- DISEASE: Amyotrophic lateral sclerosis 10 (ALS10) [MIM:612069]: A
CC       neurodegenerative disorder affecting upper motor neurons in the brain
CC       and lower motor neurons in the brain stem and spinal cord, resulting in
CC       fatal paralysis. Sensory abnormalities are absent. The pathologic
CC       hallmarks of the disease include pallor of the corticospinal tract due
CC       to loss of motor neurons, presence of ubiquitin-positive inclusions
CC       within surviving motor neurons, and deposition of pathologic
CC       aggregates. The etiology of amyotrophic lateral sclerosis is likely to
CC       be multifactorial, involving both genetic and environmental factors.
CC       The disease is inherited in 5-10% of the cases.
CC       {ECO:0000269|PubMed:18288693, ECO:0000269|PubMed:18309045,
CC       ECO:0000269|PubMed:18372902, ECO:0000269|PubMed:18396105,
CC       ECO:0000269|PubMed:18438952, ECO:0000269|PubMed:19224587,
CC       ECO:0000269|PubMed:19350673, ECO:0000269|PubMed:19655382,
CC       ECO:0000269|PubMed:19695877, ECO:0000269|PubMed:19760257,
CC       ECO:0000269|PubMed:20740007, ECO:0000269|PubMed:21220647,
CC       ECO:0000269|PubMed:21418058, ECO:0000269|PubMed:22456481,
CC       ECO:0000269|PubMed:25678563, ECO:0000269|PubMed:33031745}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry. Neurodegeneration is caused by activation of the cGAS-STING
CC       pathway: defects in TARDBP trigger mitochondrial DNA release into the
CC       cytosol via the permeability transition pore (PubMed:33031745).
CC       Released mitochondrial DNA is then detected by CGAS, leading to
CC       activation of the cGAS-STING pathway, triggering type-I interferon
CC       production and autoinflammation (PubMed:33031745).
CC       {ECO:0000269|PubMed:33031745}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=ABO32290.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC       Sequence=ABO32292.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U23731; AAA70033.1; -; mRNA.
DR   EMBL; EF434181; ABO32290.1; ALT_SEQ; mRNA.
DR   EMBL; EF434182; ABO32291.1; -; mRNA.
DR   EMBL; EF434183; ABO32292.1; ALT_SEQ; mRNA.
DR   EMBL; AK295920; BAG58707.1; -; mRNA.
DR   EMBL; AK312416; BAG35326.1; -; mRNA.
DR   EMBL; CR533534; CAG38565.1; -; mRNA.
DR   EMBL; AK222754; BAD96474.1; -; mRNA.
DR   EMBL; AL050265; CAB43367.1; -; mRNA.
DR   EMBL; AL109811; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471130; EAW71670.1; -; Genomic_DNA.
DR   EMBL; BC071657; AAH71657.1; -; mRNA.
DR   EMBL; BC095435; AAH95435.1; -; mRNA.
DR   CCDS; CCDS122.1; -. [Q13148-1]
DR   PIR; I38977; I38977.
DR   RefSeq; NP_031401.1; NM_007375.4. [Q13148-1]
DR   RefSeq; XP_016856352.1; XM_017000863.1.
DR   RefSeq; XP_016856353.1; XM_017000864.1.
DR   RefSeq; XP_016856354.1; XM_017000865.1.
DR   RefSeq; XP_016856355.1; XM_017000866.1.
DR   RefSeq; XP_016856356.1; XM_017000867.1.
DR   RefSeq; XP_016856357.1; XM_017000868.1.
DR   PDB; 1WF0; NMR; -; A=193-267.
DR   PDB; 2CQG; NMR; -; A=96-185.
DR   PDB; 2N2C; NMR; -; A=307-349.
DR   PDB; 2N3X; NMR; -; A=311-360.
DR   PDB; 2N4G; NMR; -; A=311-360.
DR   PDB; 2N4H; NMR; -; A=311-360.
DR   PDB; 2N4P; NMR; -; A=1-77.
DR   PDB; 4BS2; NMR; -; A=102-269.
DR   PDB; 4IUF; X-ray; 2.75 A; A=103-179.
DR   PDB; 4Y00; X-ray; 3.00 A; A/B/C/D=101-191.
DR   PDB; 4Y0F; X-ray; 2.65 A; A/B=101-191.
DR   PDB; 5MDI; X-ray; 2.10 A; A/B=2-80.
DR   PDB; 5MRG; NMR; -; A=1-102.
DR   PDB; 5W50; X-ray; 1.40 A; A/B=248-253.
DR   PDB; 5W52; EM; 1.40 A; A=247-257.
DR   PDB; 5W7V; EM; 3.80 A; 0/1/2/3/4/5/6/7/8=247-257.
DR   PDB; 5WHN; X-ray; 1.10 A; A=312-317.
DR   PDB; 5WHP; X-ray; 1.00 A; A=312-317.
DR   PDB; 5WIA; X-ray; 1.00 A; A=370-375.
DR   PDB; 5WIQ; X-ray; 1.25 A; A/B=396-402.
DR   PDB; 5WKB; EM; 1.00 A; A=312-317.
DR   PDB; 5WKD; X-ray; 1.80 A; A=300-306.
DR   PDB; 5X4F; NMR; -; A=1-77.
DR   PDB; 6B1G; NMR; -; A/B=1-80.
DR   PDB; 6CF4; EM; 0.75 A; A=312-317.
DR   PDB; 6CFH; EM; 1.50 A; A/B=333-343.
DR   PDB; 6N37; EM; 3.80 A; A/B/C/D/E/F/G/H/I/J=311-360.
DR   PDB; 6N3A; EM; 3.30 A; A/B/C/D/E/F/G/H/I/J=311-360.
DR   PDB; 6N3B; EM; 3.80 A; A/B/C/D/E/F/G/H/I/J=311-360.
DR   PDB; 6N3C; EM; 3.30 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T=286-331.
DR   PDB; 6T4B; X-ray; 2.55 A; A/C/E/G/I=1-80.
DR   PDB; 7KWZ; EM; 3.20 A; A/B/C/D/E=267-414.
DR   PDB; 7N9H; X-ray; 2.20 A; A=79-102.
DR   PDB; 7PY2; EM; 2.60 A; A/B/C/D=1-414.
DR   PDB; 7Q3U; EM; 3.70 A; A/B/C/D/E=279-360.
DR   PDB; 8A6I; NMR; -; A=309-350.
DR   PDB; 8CG3; EM; 2.39 A; A/B/C/D/U=1-414.
DR   PDB; 8CGG; EM; 2.50 A; A/B/C/D/U=1-414.
DR   PDB; 8CGH; EM; 2.68 A; A/B/C/D/U=1-414.
DR   PDB; 8QX9; EM; 3.76 A; A/B/C/D/E/F/G/H/I/J/K/L=1-414.
DR   PDB; 8QXA; EM; 4.05 A; A/B/C/D/E/F/G/H/I/J/K/L=1-414.
DR   PDB; 8QXB; EM; 3.86 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R=1-414.
DR   PDB; 9FOF; EM; 2.90 A; A/C/E/G/I/q=282-345.
DR   PDB; 9FOR; EM; 2.75 A; A/C/E/G/o=284-345.
DR   PDBsum; 1WF0; -.
DR   PDBsum; 2CQG; -.
DR   PDBsum; 2N2C; -.
DR   PDBsum; 2N3X; -.
DR   PDBsum; 2N4G; -.
DR   PDBsum; 2N4H; -.
DR   PDBsum; 2N4P; -.
DR   PDBsum; 4BS2; -.
DR   PDBsum; 4IUF; -.
DR   PDBsum; 4Y00; -.
DR   PDBsum; 4Y0F; -.
DR   PDBsum; 5MDI; -.
DR   PDBsum; 5MRG; -.
DR   PDBsum; 5W50; -.
DR   PDBsum; 5W52; -.
DR   PDBsum; 5W7V; -.
DR   PDBsum; 5WHN; -.
DR   PDBsum; 5WHP; -.
DR   PDBsum; 5WIA; -.
DR   PDBsum; 5WIQ; -.
DR   PDBsum; 5WKB; -.
DR   PDBsum; 5WKD; -.
DR   PDBsum; 5X4F; -.
DR   PDBsum; 6B1G; -.
DR   PDBsum; 6CF4; -.
DR   PDBsum; 6CFH; -.
DR   PDBsum; 6N37; -.
DR   PDBsum; 6N3A; -.
DR   PDBsum; 6N3B; -.
DR   PDBsum; 6N3C; -.
DR   PDBsum; 6T4B; -.
DR   PDBsum; 7KWZ; -.
DR   PDBsum; 7N9H; -.
DR   PDBsum; 7PY2; -.
DR   PDBsum; 7Q3U; -.
DR   PDBsum; 8A6I; -.
DR   PDBsum; 8CG3; -.
DR   PDBsum; 8CGG; -.
DR   PDBsum; 8CGH; -.
DR   PDBsum; 8QX9; -.
DR   PDBsum; 8QXA; -.
DR   PDBsum; 8QXB; -.
DR   PDBsum; 9FOF; -.
DR   PDBsum; 9FOR; -.
DR   AlphaFoldDB; Q13148; -.
DR   BMRB; Q13148; -.
DR   EMDB; EMD-0334; -.
DR   EMDB; EMD-13708; -.
DR   EMDB; EMD-13795; -.
DR   EMDB; EMD-16628; -.
DR   EMDB; EMD-16642; -.
DR   EMDB; EMD-16643; -.
DR   EMDB; EMD-18715; -.
DR   EMDB; EMD-18716; -.
DR   EMDB; EMD-18717; -.
DR   EMDB; EMD-23059; -.
DR   EMDB; EMD-50621; -.
DR   EMDB; EMD-50628; -.
DR   EMDB; EMD-7467; -.
DR   EMDB; EMD-8765; -.
DR   EMDB; EMD-8781; -.
DR   EMDB; EMD-8857; -.
DR   EMDB; EMD-9339; -.
DR   EMDB; EMD-9349; -.
DR   EMDB; EMD-9350; -.
DR   SMR; Q13148; -.
DR   BioGRID; 117003; 567.
DR   CORUM; Q13148; -.
DR   DIP; DIP-31167N; -.
DR   FunCoup; Q13148; 5279.
DR   IntAct; Q13148; 297.
DR   MINT; Q13148; -.
DR   STRING; 9606.ENSP00000240185; -.
DR   BindingDB; Q13148; -.
DR   ChEMBL; CHEMBL2362981; -.
DR   DrugCentral; Q13148; -.
DR   GlyGen; Q13148; 3 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; Q13148; -.
DR   MetOSite; Q13148; -.
DR   PhosphoSitePlus; Q13148; -.
DR   SwissPalm; Q13148; -.
DR   BioMuta; TARDBP; -.
DR   DMDM; 20140568; -.
DR   jPOST; Q13148; -.
DR   MassIVE; Q13148; -.
DR   PaxDb; 9606-ENSP00000240185; -.
DR   PeptideAtlas; Q13148; -.
DR   ProteomicsDB; 4344; -.
DR   ProteomicsDB; 59189; -. [Q13148-1]
DR   Pumba; Q13148; -.
DR   ABCD; Q13148; 22 sequenced antibodies.
DR   Antibodypedia; 1854; 1017 antibodies from 46 providers.
DR   DNASU; 23435; -.
DR   YCharOS; Q13148; Tested 18 antibodies from 8 manufacturers.
DR   Ensembl; ENST00000240185.8; ENSP00000240185.4; ENSG00000120948.19. [Q13148-1]
DR   Ensembl; ENST00000639083.1; ENSP00000491203.1; ENSG00000120948.19. [Q13148-1]
DR   GeneID; 23435; -.
DR   KEGG; hsa:23435; -.
DR   MANE-Select; ENST00000240185.8; ENSP00000240185.4; NM_007375.4; NP_031401.1.
DR   UCSC; uc001art.4; human. [Q13148-1]
DR   AGR; HGNC:11571; -.
DR   CTD; 23435; -.
DR   DisGeNET; 23435; -.
DR   GeneCards; TARDBP; -.
DR   GeneReviews; TARDBP; -.
DR   HGNC; HGNC:11571; TARDBP.
DR   HPA; ENSG00000120948; Low tissue specificity.
DR   MalaCards; TARDBP; -.
DR   MIM; 605078; gene.
DR   MIM; 612069; phenotype.
DR   OpenTargets; ENSG00000120948; -.
DR   Orphanet; 803; Amyotrophic lateral sclerosis.
DR   Orphanet; 275872; Frontotemporal dementia with motor neuron disease.
DR   VEuPathDB; HostDB:ENSG00000120948; -.
DR   eggNOG; ENOG502QPQ8; Eukaryota.
DR   GeneTree; ENSGT00940000154343; -.
DR   HOGENOM; CLU_012062_6_1_1; -.
DR   InParanoid; Q13148; -.
DR   OMA; WGSASNP; -.
DR   PAN-GO; Q13148; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; Q13148; -.
DR   PathwayCommons; Q13148; -.
DR   SignaLink; Q13148; -.
DR   SIGNOR; Q13148; -.
DR   BioGRID-ORCS; 23435; 724 hits in 1132 CRISPR screens.
DR   CD-CODE; 0A6B6B10; Synthetic Condensate 000350.
DR   CD-CODE; 1A18FFC4; Paraspeckle.
DR   CD-CODE; 232F8A39; P-body.
DR   CD-CODE; 29DC92C3; Synthetic Condensate 000232.
DR   CD-CODE; 4CAAAA97; Synthetic Condensate 000349.
DR   CD-CODE; 6209F224; Synthetic Condensate 000281.
DR   CD-CODE; 6F24707C; Cajal body.
DR   CD-CODE; 85C30F04; Synthetic Condensate 000057.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; 95CA54FE; Synthetic Condensate 000215.
DR   CD-CODE; 9B5E283A; Synthetic Condensate 000373.
DR   CD-CODE; BEB5E62D; Anisosome.
DR   CD-CODE; C4C56ED2; TDP-25 inclusions.
DR   CD-CODE; CC266C53; Synthetic Condensate 000179.
DR   CD-CODE; D8E9712B; Neuronal RNP granule.
DR   CD-CODE; DEE660B4; Stress granule.
DR   CD-CODE; E1879998; Synthetic Condensate 000375.
DR   CD-CODE; E3E4F6CC; Synthetic Condensate 000302.
DR   CD-CODE; ED4B3785; Synthetic Condensate 000058.
DR   CD-CODE; F15C9420; Synthetic Condensate 000300.
DR   CD-CODE; F50842E4; Synthetic Condensate 000357.
DR   CD-CODE; F85A2E29; IMP1 RNP granule.
DR   ChiTaRS; TARDBP; human.
DR   EvolutionaryTrace; Q13148; -.
DR   GeneWiki; TARDBP; -.
DR   GenomeRNAi; 23435; -.
DR   Pharos; Q13148; Tchem.
DR   PRO; PR:Q13148; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q13148; protein.
DR   Bgee; ENSG00000120948; Expressed in secondary oocyte and 207 other cell types or tissues.
DR   ExpressionAtlas; Q13148; baseline and differential.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0010494; C:cytoplasmic stress granule; IEA:UniProtKB-SubCell.
DR   GO; GO:0035061; C:interchromatin granule; IEA:Ensembl.
DR   GO; GO:0043232; C:intracellular membraneless organelle; IDA:DisProt.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0016607; C:nuclear speck; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005726; C:perichromatin fibrils; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; EXP:DisProt.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008289; F:lipid binding; EXP:DisProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:BHF-UCL.
DR   GO; GO:0097157; F:pre-mRNA intronic binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; IDA:BHF-UCL.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0061158; P:3'-UTR-mediated mRNA destabilization; IDA:CACAO.
DR   GO; GO:0070935; P:3'-UTR-mediated mRNA stabilization; IDA:BHF-UCL.
DR   GO; GO:1990000; P:amyloid fibril formation; IDA:DisProt.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0043922; P:negative regulation by host of viral transcription; IDA:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:CACAO.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IMP:CACAO.
DR   GO; GO:0071765; P:nuclear inner membrane organization; IMP:CACAO.
DR   GO; GO:0032024; P:positive regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:CACAO.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:CACAO.
DR   GO; GO:0042752; P:regulation of circadian rhythm; IEA:Ensembl.
DR   GO; GO:0010468; P:regulation of gene expression; IBA:GO_Central.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0008380; P:RNA splicing; IDA:BHF-UCL.
DR   CDD; cd19609; NTD_TDP-43; 1.
DR   CDD; cd12321; RRM1_TDP43; 1.
DR   CDD; cd12322; RRM2_TDP43; 1.
DR   DisProt; DP01108; -.
DR   FunFam; 3.30.70.330:FF:000098; TAR DNA-binding protein 43; 1.
DR   FunFam; 3.30.70.330:FF:000107; TAR DNA-binding protein 43; 1.
DR   Gene3D; 3.30.70.330; -; 2.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR000504; RRM_dom.
DR   InterPro; IPR049124; TDP-43_C.
DR   InterPro; IPR041105; TDP-43_N.
DR   PANTHER; PTHR48033; RNA-BINDING (RRM/RBD/RNP MOTIFS) FAMILY PROTEIN; 1.
DR   PANTHER; PTHR48033:SF9; TAR DNA-BINDING PROTEIN 43; 1.
DR   Pfam; PF00076; RRM_1; 2.
DR   Pfam; PF20910; TDP-43_C; 1.
DR   Pfam; PF18694; TDP-43_N; 1.
DR   SMART; SM00360; RRM; 2.
DR   SUPFAM; SSF54928; RNA-binding domain, RBD; 2.
DR   PROSITE; PS50102; RRM; 2.
DR   neXtProt; NX_Q13148; -.
DR   PharmGKB; PA36336; -.
DR   TreeFam; TF315657; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Amyotrophic lateral sclerosis;
KW   Biological rhythms; Cytoplasm; Direct protein sequencing; Disease variant;
KW   DNA-binding; Isopeptide bond; Methylation; Mitochondrion; mRNA processing;
KW   mRNA splicing; Neurodegeneration; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Repeat; Repressor;
KW   RNA-binding; Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..414
FT                   /note="TAR DNA-binding protein 43"
FT                   /id="PRO_0000081972"
FT   DOMAIN          104..200
FT                   /note="RRM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          191..262
FT                   /note="RRM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   REGION          216..414
FT                   /note="Interaction with UBQLN2"
FT                   /evidence="ECO:0000269|PubMed:23541532"
FT   REGION          261..303
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          341..373
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           82..98
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000269|PubMed:18957508"
FT   MOTIF           239..250
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000269|PubMed:18957508"
FT   COMPBIAS        261..274
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        275..303
FT                   /note="Gly residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        342..358
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         183
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         292
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         293
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   CROSSLNK        79
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        84
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        95
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        102
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364"
FT   CROSSLNK        181
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        263
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..18
FT                   /note="MSEYIRVTEDENDEPIEI -> MPQMLAGEIWCMLSTIQK (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056406"
FT   VAR_SEQ         19..134
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056407"
FT   VARIANT         90
FT                   /note="A -> V (in dbSNP:rs80356715)"
FT                   /evidence="ECO:0000269|PubMed:18309045,
FT                   ECO:0000269|PubMed:18372902, ECO:0000269|PubMed:19760257,
FT                   ECO:0000269|PubMed:22456481"
FT                   /id="VAR_045656"
FT   VARIANT         169
FT                   /note="D -> G (in ALS10; dbSNP:rs80356717)"
FT                   /evidence="ECO:0000269|PubMed:18372902"
FT                   /id="VAR_045657"
FT   VARIANT         267
FT                   /note="N -> S (in ALS10; also in a patient with
FT                   frontotemporal dementia; dbSNP:rs80356718)"
FT                   /evidence="ECO:0000269|PubMed:19224587"
FT                   /id="VAR_058611"
FT   VARIANT         287
FT                   /note="G -> S (in ALS10; loss of ability to negatively
FT                   regulate the expression of CDK6; dbSNP:rs80356719)"
FT                   /evidence="ECO:0000269|PubMed:18372902,
FT                   ECO:0000269|PubMed:19224587, ECO:0000269|PubMed:19760257"
FT                   /id="VAR_045658"
FT   VARIANT         290
FT                   /note="G -> A (in ALS10; dbSNP:rs121908395)"
FT                   /evidence="ECO:0000269|PubMed:18396105"
FT                   /id="VAR_045659"
FT   VARIANT         294
FT                   /note="G -> A (in ALS10; dbSNP:rs80356721)"
FT                   /evidence="ECO:0000269|PubMed:18309045,
FT                   ECO:0000269|PubMed:19695877"
FT                   /id="VAR_045660"
FT   VARIANT         294
FT                   /note="G -> V (in ALS10; a patient with bulbar signs and
FT                   dementia; dbSNP:rs80356721)"
FT                   /evidence="ECO:0000269|PubMed:19224587"
FT                   /id="VAR_058612"
FT   VARIANT         295
FT                   /note="G -> R (in ALS10; dbSNP:rs80356723)"
FT                   /evidence="ECO:0000269|PubMed:19224587"
FT                   /id="VAR_058613"
FT   VARIANT         295
FT                   /note="G -> S (in ALS10; also in patients with
FT                   frontotemporal lobar degeneration with motor neuron
FT                   disease; dbSNP:rs80356723)"
FT                   /evidence="ECO:0000269|PubMed:19224587"
FT                   /id="VAR_058614"
FT   VARIANT         298
FT                   /note="G -> S (in ALS10; dbSNP:rs4884357)"
FT                   /evidence="ECO:0000269|PubMed:18396105"
FT                   /id="VAR_045661"
FT   VARIANT         315
FT                   /note="A -> T (in ALS10; triggers mitochondrial DNA release
FT                   into the cytosol, which is then detected by CGAS, leading
FT                   to activation of the cGAS-STING pathway and
FT                   autoinflammation; slight reduction in interaction with
FT                   PPIA/CYPA; dbSNP:rs80356726)"
FT                   /evidence="ECO:0000269|PubMed:18288693,
FT                   ECO:0000269|PubMed:18372902, ECO:0000269|PubMed:25678563,
FT                   ECO:0000269|PubMed:33031745"
FT                   /id="VAR_045662"
FT   VARIANT         321
FT                   /note="A -> V (in ALS10; loss of ability to negatively
FT                   regulate the expression of CDK6)"
FT                   /evidence="ECO:0000269|PubMed:19760257"
FT                   /id="VAR_083737"
FT   VARIANT         331
FT                   /note="Q -> K (in ALS10; triggers mitochondrial DNA release
FT                   into the cytosol, which is then detected by CGAS, leading
FT                   to activation of the cGAS-STING pathway and
FT                   autoinflammation; impedes the development of normal limb
FT                   and tail buds and increases the number of apoptotic nuclei
FT                   when expressed in chick embryos; does not affect the
FT                   interaction with ATXN2; dbSNP:rs80356727)"
FT                   /evidence="ECO:0000269|PubMed:18309045,
FT                   ECO:0000269|PubMed:20740007, ECO:0000269|PubMed:33031745"
FT                   /id="VAR_045663"
FT   VARIANT         332
FT                   /note="S -> N (in ALS10; dbSNP:rs80356728)"
FT                   /evidence="ECO:0000269|PubMed:19224587"
FT                   /id="VAR_058615"
FT   VARIANT         335
FT                   /note="G -> D (in ALS10; dbSNP:rs80356729)"
FT                   /evidence="ECO:0000269|PubMed:19224587"
FT                   /id="VAR_058616"
FT   VARIANT         337
FT                   /note="M -> V (in ALS10; impedes the development of normal
FT                   limb and tail buds and increases the number of apoptotic
FT                   nuclei when expressed in chick embryos; loss of ability to
FT                   negatively regulate the expression of CDK6;
FT                   dbSNP:rs80356730)"
FT                   /evidence="ECO:0000269|PubMed:18309045,
FT                   ECO:0000269|PubMed:19224587, ECO:0000269|PubMed:19760257"
FT                   /id="VAR_045664"
FT   VARIANT         343
FT                   /note="Q -> R (in ALS10; dbSNP:rs80356731)"
FT                   /evidence="ECO:0000269|PubMed:18438952"
FT                   /id="VAR_062767"
FT   VARIANT         348
FT                   /note="G -> C (in ALS10; dbSNP:rs80356733)"
FT                   /evidence="ECO:0000269|PubMed:18372902"
FT                   /id="VAR_045665"
FT   VARIANT         348
FT                   /note="G -> V (in ALS10; loss of interaction with
FT                   PPIA/CYPA)"
FT                   /evidence="ECO:0000269|PubMed:19760257,
FT                   ECO:0000269|PubMed:25678563"
FT                   /id="VAR_083738"
FT   VARIANT         357
FT                   /note="G -> R (in ALS10)"
FT                   /evidence="ECO:0000269|PubMed:22456481"
FT                   /id="VAR_067499"
FT   VARIANT         361
FT                   /note="R -> S (in ALS10; significant reduction in
FT                   interaction with PPIA/CYPA; dbSNP:rs80356735)"
FT                   /evidence="ECO:0000269|PubMed:18372902,
FT                   ECO:0000269|PubMed:25678563"
FT                   /id="VAR_045666"
FT   VARIANT         361
FT                   /note="R -> T (in ALS10)"
FT                   /evidence="ECO:0000269|PubMed:22456481"
FT                   /id="VAR_067500"
FT   VARIANT         379
FT                   /note="S -> C (in ALS10; dbSNP:rs80356739)"
FT                   /evidence="ECO:0000269|PubMed:19224587"
FT                   /id="VAR_058617"
FT   VARIANT         379
FT                   /note="S -> P (in ALS10; dbSNP:rs80356738)"
FT                   /evidence="ECO:0000269|PubMed:19224587,
FT                   ECO:0000269|PubMed:22456481"
FT                   /id="VAR_058618"
FT   VARIANT         382
FT                   /note="A -> T (in ALS10; dbSNP:rs367543041)"
FT                   /evidence="ECO:0000269|PubMed:18372902,
FT                   ECO:0000269|PubMed:19224587, ECO:0000269|PubMed:21220647,
FT                   ECO:0000269|PubMed:21418058"
FT                   /id="VAR_045667"
FT   VARIANT         390
FT                   /note="N -> D (in ALS10; dbSNP:rs80356741)"
FT                   /evidence="ECO:0000269|PubMed:18372902"
FT                   /id="VAR_045668"
FT   VARIANT         390
FT                   /note="N -> S (in ALS10; dbSNP:rs80356742)"
FT                   /evidence="ECO:0000269|PubMed:18372902"
FT                   /id="VAR_045669"
FT   VARIANT         393
FT                   /note="S -> L (in ALS10; dbSNP:rs80356743)"
FT                   /evidence="ECO:0000269|PubMed:19224587"
FT                   /id="VAR_058619"
FT   MUTAGEN         48
FT                   /note="S->E: Complete loss of self-oligomerization."
FT                   /evidence="ECO:0000269|PubMed:29438978"
FT   MUTAGEN         103..183
FT                   /note="Missing: Loss of RNA-binding and reduced interaction
FT                   with PPIA/CYPA."
FT                   /evidence="ECO:0000269|PubMed:25678563"
FT   MUTAGEN         106..175
FT                   /note="Missing: Completely abolishes RNA binding."
FT                   /evidence="ECO:0000269|PubMed:11470789"
FT   MUTAGEN         106..111
FT                   /note="LIVLGL->DIDLGD: Completely abolishes RNA binding."
FT                   /evidence="ECO:0000269|PubMed:11470789"
FT   MUTAGEN         106..111
FT                   /note="Missing: Completely abolishes RNA binding."
FT                   /evidence="ECO:0000269|PubMed:11470789"
FT   MUTAGEN         147..149
FT                   /note="FGF->LGL: Highly reduces binding to RNA and DNA."
FT                   /evidence="ECO:0000269|PubMed:11470789"
FT   MUTAGEN         193..257
FT                   /note="Missing: Alters but does not abolish RNA binding."
FT                   /evidence="ECO:0000269|PubMed:11470789"
FT   CONFLICT        200
FT                   /note="E -> G (in Ref. 5; BAD96474)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        278
FT                   /note="G -> V (in Ref. 3; BAG35326)"
FT                   /evidence="ECO:0000305"
FT   STRAND          4..10
FT                   /evidence="ECO:0007829|PDB:5MDI"
FT   STRAND          16..19
FT                   /evidence="ECO:0007829|PDB:5MDI"
FT   STRAND          22..24
FT                   /evidence="ECO:0007829|PDB:2N4P"
FT   STRAND          25..27
FT                   /evidence="ECO:0007829|PDB:5X4F"
FT   HELIX           28..32
FT                   /evidence="ECO:0007829|PDB:5MDI"
FT   STRAND          33..37
FT                   /evidence="ECO:0007829|PDB:5X4F"
FT   STRAND          40..44
FT                   /evidence="ECO:0007829|PDB:5MDI"
FT   TURN            46..48
FT                   /evidence="ECO:0007829|PDB:5MDI"
FT   STRAND          50..53
FT                   /evidence="ECO:0007829|PDB:5MDI"
FT   STRAND          55..57
FT                   /evidence="ECO:0007829|PDB:5MDI"
FT   STRAND          60..62
FT                   /evidence="ECO:0007829|PDB:5MDI"
FT   STRAND          65..67
FT                   /evidence="ECO:0007829|PDB:5X4F"
FT   TURN            69..71
FT                   /evidence="ECO:0007829|PDB:6B1G"
FT   STRAND          72..76
FT                   /evidence="ECO:0007829|PDB:5MDI"
FT   STRAND          87..89
FT                   /evidence="ECO:0007829|PDB:7N9H"
FT   STRAND          106..110
FT                   /evidence="ECO:0007829|PDB:4Y0F"
FT   HELIX           117..124
FT                   /evidence="ECO:0007829|PDB:4Y0F"
FT   TURN            125..127
FT                   /evidence="ECO:0007829|PDB:4Y0F"
FT   STRAND          130..137
FT                   /evidence="ECO:0007829|PDB:4Y0F"
FT   TURN            139..141
FT                   /evidence="ECO:0007829|PDB:4Y0F"
FT   STRAND          144..154
FT                   /evidence="ECO:0007829|PDB:4Y0F"
FT   HELIX           155..162
FT                   /evidence="ECO:0007829|PDB:4Y0F"
FT   STRAND          166..168
FT                   /evidence="ECO:0007829|PDB:4Y0F"
FT   STRAND          171..176
FT                   /evidence="ECO:0007829|PDB:4Y0F"
FT   STRAND          193..197
FT                   /evidence="ECO:0007829|PDB:1WF0"
FT   STRAND          200..202
FT                   /evidence="ECO:0007829|PDB:1WF0"
FT   HELIX           204..210
FT                   /evidence="ECO:0007829|PDB:1WF0"
FT   TURN            212..214
FT                   /evidence="ECO:0007829|PDB:1WF0"
FT   STRAND          219..221
FT                   /evidence="ECO:0007829|PDB:1WF0"
FT   STRAND          231..233
FT                   /evidence="ECO:0007829|PDB:1WF0"
FT   HELIX           237..242
FT                   /evidence="ECO:0007829|PDB:1WF0"
FT   TURN            243..245
FT                   /evidence="ECO:0007829|PDB:1WF0"
FT   STRAND          247..250
FT                   /evidence="ECO:0007829|PDB:1WF0"
FT   STRAND          253..258
FT                   /evidence="ECO:0007829|PDB:1WF0"
FT   STRAND          263..265
FT                   /evidence="ECO:0007829|PDB:4BS2"
FT   STRAND          273..275
FT                   /evidence="ECO:0007829|PDB:8CG3"
FT   STRAND          283..285
FT                   /evidence="ECO:0007829|PDB:7PY2"
FT   STRAND          288..290
FT                   /evidence="ECO:0007829|PDB:8CG3"
FT   STRAND          292..294
FT                   /evidence="ECO:0007829|PDB:8CG3"
FT   STRAND          296..300
FT                   /evidence="ECO:0007829|PDB:8CG3"
FT   STRAND          302..305
FT                   /evidence="ECO:0007829|PDB:7KWZ"
FT   STRAND          306..316
FT                   /evidence="ECO:0007829|PDB:8CG3"
FT   STRAND          321..331
FT                   /evidence="ECO:0007829|PDB:8CGG"
FT   STRAND          334..342
FT                   /evidence="ECO:0007829|PDB:6CFH"
FT   STRAND          343..347
FT                   /evidence="ECO:0007829|PDB:8CG3"
FT   STRAND          348..350
FT                   /evidence="ECO:0007829|PDB:2N3X"
FT   STRAND          353..356
FT                   /evidence="ECO:0007829|PDB:8CG3"
FT   STRAND          367..370
FT                   /evidence="ECO:0007829|PDB:7KWZ"
FT   STRAND          373..378
FT                   /evidence="ECO:0007829|PDB:7KWZ"
FT   STRAND          382..384
FT                   /evidence="ECO:0007829|PDB:7KWZ"
FT   STRAND          389..395
FT                   /evidence="ECO:0007829|PDB:7KWZ"
FT   STRAND          405..412
FT                   /evidence="ECO:0007829|PDB:7KWZ"
SQ   SEQUENCE   414 AA;  44740 MW;  8E09A1206FB4EF4A CRC64;
     MSEYIRVTED ENDEPIEIPS EDDGTVLLST VTAQFPGACG LRYRNPVSQC MRGVRLVEGI
     LHAPDAGWGN LVYVVNYPKD NKRKMDETDA SSAVKVKRAV QKTSDLIVLG LPWKTTEQDL
     KEYFSTFGEV LMVQVKKDLK TGHSKGFGFV RFTEYETQVK VMSQRHMIDG RWCDCKLPNS
     KQSQDEPLRS RKVFVGRCTE DMTEDELREF FSQYGDVMDV FIPKPFRAFA FVTFADDQIA
     QSLCGEDLII KGISVHISNA EPKHNSNRQL ERSGRFGGNP GGFGNQGGFG NSRGGGAGLG
     NNQGSNMGGG MNFGAFSINP AMMAAAQAAL QSSWGMMGML ASQQNQSGPS GNNQNQGNMQ
     REPNQAFGSG NNSYSGSNSG AAIGWGSASN AGSGSGFNGG FGSSMDSKSS GWGM
//
